Edgardo Baracchini, Jr. Sells 10,000 Shares of Xencor Inc. (XNCR) Stock
Xencor Inc. (NASDAQ:XNCR) insider Edgardo Baracchini, Jr. sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 28th. The shares were sold at an average price of $25.35, for a total value of $253,500.00. Following the completion of the sale, the insider now owns 10,000 shares of the company’s stock, valued at $253,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Edgardo Baracchini, Jr. also recently made the following trade(s):
- On Wednesday, August 3rd, Edgardo Baracchini, Jr. sold 4,528 shares of Xencor stock. The shares were sold at an average price of $20.00, for a total value of $90,560.00.
Shares of Xencor Inc. (NASDAQ:XNCR) opened at 24.38 on Friday. Xencor Inc. has a 12 month low of $9.89 and a 12 month high of $26.50. The stock has a market capitalization of $998.34 million, a PE ratio of 25.91 and a beta of 2.14. The company’s 50 day moving average price is $22.63 and its 200 day moving average price is $16.91.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $1.31. The firm earned $66 million during the quarter, compared to analysts’ expectations of $7.43 million. Xencor had a return on equity of 22.53% and a net margin of 39.07%. Equities analysts anticipate that Xencor Inc. will post $0.72 earnings per share for the current fiscal year.
XNCR has been the subject of a number of recent analyst reports. Wedbush restated an “outperform” rating and issued a $27.00 price objective on shares of Xencor in a research report on Tuesday, June 28th. Zacks Investment Research upgraded Xencor from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research report on Tuesday, July 5th. Canaccord Genuity set a $27.00 price objective on Xencor and gave the company a “buy” rating in a research report on Monday, September 12th. Finally, Leerink Swann restated an “outperform” rating and issued a $18.00 price objective on shares of Xencor in a research report on Wednesday, June 29th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $23.50.
Institutional investors have recently modified their holdings of the company. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new position in shares of Xencor during the second quarter valued at about $414,000. Emerald Acquisition Ltd. purchased a new position in shares of Xencor during the second quarter valued at about $960,000. Swiss National Bank boosted its position in shares of Xencor by 13.2% in the second quarter. Swiss National Bank now owns 54,800 shares of the biopharmaceutical company’s stock valued at $1,041,000 after buying an additional 6,400 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Xencor by 11.9% in the second quarter. California State Teachers Retirement System now owns 67,434 shares of the biopharmaceutical company’s stock valued at $1,281,000 after buying an additional 7,167 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Xencor by 5.5% in the second quarter. Bank of New York Mellon Corp now owns 132,627 shares of the biopharmaceutical company’s stock valued at $2,519,000 after buying an additional 6,965 shares in the last quarter. 67.72% of the stock is owned by hedge funds and other institutional investors.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.
Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.